Welcome to our dedicated page for Zero Candida Technologies news (Ticker: ZCTFF), a resource for investors and traders seeking the latest updates and insights on Zero Candida Technologies stock.
Zero Candida Technologies, Inc. (OTCQB: ZCTFF) is a publicly traded FemTech medical device company focused on women’s health, with a core program targeting Vulvo-Vaginal Candidiasis (VVC). This news page aggregates company-issued updates and market announcements related to its AI-enabled, tampon-like therapeutic device platform and corporate milestones.
Readers can find news about Zero Candida’s progress with its ZC-001 therapeutic device, including design freeze announcements, prototype production, and pre-clinical validation activities. The company has highlighted features such as blue light therapy at a precise wavelength and intensity, targeted drug delivery, wireless diagnostics, and a SMART docking and charging case, all of which appear in its development updates.
In addition to product and clinical news, Zero Candida regularly reports on its regulatory and capital markets developments. Examples include its listings on the TSX Venture Exchange, OTCQB Venture Market, and Frankfurt Stock Exchange, as well as DTC eligibility for electronic clearing and settlement of its common shares in the United States. Business updates may also cover its De Novo regulatory pathway plans, partnerships with hospitals in Europe and Israel, and discussions with U.S. hospitals and pharmaceutical companies.
Investors and observers can use this page to follow Zero Candida’s financial disclosures, such as quarterly and annual results, along with commentary on research and development spending and progress as a development-stage company. By reviewing the news feed, users can track how the company describes its advancement toward clinical trials, expansion of its patent portfolio, and positioning within the VVC treatment market.
Zero Candida Technologies (OTCQB: ZCTFF) scaled manufacturing to 250 ISO 13485 clinical‑grade prototypes of its ZC-001 therapeutic device, with completion expected within 90 days.
The production supports GLP preclinical testing and remains on track for a targeted Q4 2026 clinical study of at least 100 women, building on prior lab results showing 99.999% fungal eradication under controlled conditions.
Zero Candida Technologies (OTCQB: ZCTFF) announced a design freeze for its ZC-001 AI-enabled therapeutic device and has begun prototype production on Oct 20, 2025. The company started manufacturing 50 prototype units with completion expected by Q1 2026. The design freeze finalizes device and SMART docking case specifications and sets technical standards for validation and regulatory pathway progression.
Key features include blue light therapy, targeted drug delivery, wireless diagnostics with encrypted data transmission, docking alignment for charging and dosing accuracy, medical-grade materials, and modular assembly for scalable manufacturing.
Zero Candida Technologies (OTCQB: ZCTFF), a Femtech company developing an AI-powered medical device for women's gynecological health, reported its Q2 2025 financial results. The company reported a Q2 operating loss of $0.31 million, improved from $0.35 million in Q2 2024, while cash position strengthened to $0.46 million from $0.24 million at year-end 2024.
The company outlined key development milestones including final preclinical results by Q2 2026, laboratory validation studies in Q3 2026, pilot clinical trials in Israel by Q4 2026, and U.S. targeted clinical trials by Q3 2027. Management confirms sufficient resources to support operations for the next 12 months, with working capital of $1.53 million and total assets of $2.77 million.
Zero Candida Technologies (OTCQB: ZCTFF), a FemTech medical device company, has announced two key developments: achieving DTC eligibility for its common shares and an upcoming presentation at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.
The DTC eligibility enables electronic clearing and settlement of shares in the United States, improving trading efficiency and reducing settlement times. This development aims to enhance liquidity and reduce transaction costs while making shares more accessible to U.S. investors, particularly institutions requiring DTC eligibility.
Zero Candida Technologies (ZCTFF) reported its full-year 2024 financial results, marking a transformative year with key achievements. The company completed its public listing and achieved important pre-clinical milestones for its women's health medical device.
Financial highlights include:
- R&D expenses: CAD 1,276,000 (vs CAD 1,868,000 in 2023)
- G&A expenses: CAD 965,000 (vs CAD 649,000 in 2023)
- Operating loss: CAD 6,241,000 (vs CAD 2,517,000 in 2023)
- Net loss: CAD 6,283,000 (vs CAD 2,513,000 in 2023)
- Cash position: CAD 3,052,000 (vs CAD 1,639,000 in 2023)
Key 2024 developments include successful completion of a reverse merger acquisition for CAD 4 million, listing on TSXV, obtaining a final patent in South Africa for the ZC-01 device, and receiving positive pre-clinical safety study results from Shamir Medical Centre.
Zero Candida Technologies (ZCTFF) has announced the commencement of trading on the OTCQB Venture Market under the ticker symbol 'ZCTFF', while maintaining its listings on the TSX Venture Exchange and Frankfurt Stock Exchange.
The OTCQB, operated by OTC Markets Group and recognized by the SEC, serves as a premier market for early-stage and development-stage companies. Listed companies must maintain current financial reporting, meet compliance requirements, and complete annual verification processes.
CEO Eli Ben Haroosh highlighted this milestone as strategic for the company's long-term growth, emphasizing their focus on expanding market presence and partnerships. The listing aligns with their recent patent advancements and aims to capitalize on the growing VVC treatment market, particularly in the U.S.